TY - JOUR
T1 - Anti-inflammatory effects of caffeic acid phenethyl ester (CAPE), a nuclear factor-κB inhibitor, on Helicobacter pylori-induced gastritis in Mongolian gerbils
AU - Toyoda, Takeshi
AU - Tsukamoto, Tetsuya
AU - Takasu, Shinji
AU - Shi, Liang
AU - Hirano, Naoki
AU - Ban, Hisayo
AU - Kumagai, Toshiko
AU - Tatematsu, Masae
PY - 2009/10/15
Y1 - 2009/10/15
N2 - Nuclear factor-κB (NF-κB) plays a major role in host inflammatory responses and carcinogenesis and as such is an important drug target for adjuvant therapy. In this study, we examined the effect of caffeic acid phenethyl ester (CAPE), an NF-κB inhibitor, on Helicobacter pylori (H. pylori)-induced NF-κB activation in cell culture and chronic gastritis in Mongolian gerbils. In AGS gastric cancer cells, CAPE significantly inhibited H. pylori-stimulated NF-κB activation and mRNA expression of several inflammatory factors in a dose-dependent manner, and prevented degradation of IκB-α and phosphorylation of p65 subunit. To evaluate the effects of CAPE on H. pylori-induced gastritis, specific pathogen-free male, 6-week-old Mongolian gerbils were intragastrically inoculated with H. pylori, fed diets containing CAPE (0-0.1%) and sacrificed after 12 weeks. Infiltration of neutrophils and mononuclear cells and expression of NF-κB p50 subunit and phospho-IκB-α were significantly suppressed by 0.1% CAPE treatment in the antrum of H. pylori-infected gerbils. Labeling indices for 5′-bromo-2′-deoxyuridine both in the antrum and corpus and lengths of isolated pyloric glands were also markedly reduced at the highest dose, suggesting a preventive effect of CAPE on epithelial proliferation. Furthermore, in the pyloric mucosa, mRNA expression of inflammatory mediators including tumor necrosis factor-α, interferon-γ, interleukin (IL)-2, IL-6, KC (IL-8 homologue), and inducible nitric oxide synthase was significantly reduced. These results suggest that CAPE has inhibitory effects on H. pylori-induced gastritis in Mongolian gerbils through the suppression of NF-κB activation, and may thus have potential for prevention and therapy of H. pylori-associated gastric disorders.
AB - Nuclear factor-κB (NF-κB) plays a major role in host inflammatory responses and carcinogenesis and as such is an important drug target for adjuvant therapy. In this study, we examined the effect of caffeic acid phenethyl ester (CAPE), an NF-κB inhibitor, on Helicobacter pylori (H. pylori)-induced NF-κB activation in cell culture and chronic gastritis in Mongolian gerbils. In AGS gastric cancer cells, CAPE significantly inhibited H. pylori-stimulated NF-κB activation and mRNA expression of several inflammatory factors in a dose-dependent manner, and prevented degradation of IκB-α and phosphorylation of p65 subunit. To evaluate the effects of CAPE on H. pylori-induced gastritis, specific pathogen-free male, 6-week-old Mongolian gerbils were intragastrically inoculated with H. pylori, fed diets containing CAPE (0-0.1%) and sacrificed after 12 weeks. Infiltration of neutrophils and mononuclear cells and expression of NF-κB p50 subunit and phospho-IκB-α were significantly suppressed by 0.1% CAPE treatment in the antrum of H. pylori-infected gerbils. Labeling indices for 5′-bromo-2′-deoxyuridine both in the antrum and corpus and lengths of isolated pyloric glands were also markedly reduced at the highest dose, suggesting a preventive effect of CAPE on epithelial proliferation. Furthermore, in the pyloric mucosa, mRNA expression of inflammatory mediators including tumor necrosis factor-α, interferon-γ, interleukin (IL)-2, IL-6, KC (IL-8 homologue), and inducible nitric oxide synthase was significantly reduced. These results suggest that CAPE has inhibitory effects on H. pylori-induced gastritis in Mongolian gerbils through the suppression of NF-κB activation, and may thus have potential for prevention and therapy of H. pylori-associated gastric disorders.
UR - http://www.scopus.com/inward/record.url?scp=70349254891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349254891&partnerID=8YFLogxK
U2 - 10.1002/ijc.24586
DO - 10.1002/ijc.24586
M3 - Article
C2 - 19610061
AN - SCOPUS:70349254891
SN - 0020-7136
VL - 125
SP - 1786
EP - 1795
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 8
ER -